Overestimation of anticoagulant benefit in patients with atrial fibrillation and low life expectancy: evidence from 12 randomized trials

Sachin J. Shah, MD, MPH (1); Carl van Walraven, MD, MSc (2); Sun Young Jeon, PhD (3); W. John Boscardin, PhD (3, 4); FD Richard Hobbs, FMedSci (5), Stuart Connolly, MD (6); Michael Ezekowitz MB, ChB, DPhil (7); Kenneth E. Covinsky, MD, MPH (3); Margaret C. Fang, MD, MPH (3), Daniel E. Singer, MD (1)

(1) Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
(2) Departments of Medicine and Epidemiology & Community Medicine, University of Ottawa, Ottawa ON, CA
(3) Department of Medicine, University of California San Francisco, San Francisco, CA, USA
(4) Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA
(5) Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford UK
(6) Population Health Research Institute, McMaster University, Hamilton, ON, Canada
(7) Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA and Cardiovascular Medicine, Lankenau Institute for Medical Research, Wynnewood, PA, USA

Corresponding Author

Sachin J. Shah, MD, MPH

100 Cambridge Street, Suite 1600

Boston, MA 02114

sshah@mgh.harvard.edu

617-977-4871

Manuscript: 2939 words

Abstract: 311 words

Preprint (medRxiv): https://doi.org/10.1101/2023.02.10.23285303

ABSTRACT

Importance: Patients with atrial fibrillation have a high rate of all-cause mortality that is only

partially attributable to vascular outcomes. While the competing risk of death affects expected

anticoagulant benefit, guidelines do not account for the competing risk of death.

Objective: Compare anticoagulant benefit for patients with atrial fibrillation estimated with the

CHA_2DS_2-VASc model vs. a Competing Risk Model that accounts for the competing risk of

death and does not assume a consistent growth in treatment benefit over time

Design: Secondary analysis of randomized controlled trials (RCTs).

Setting: 12 RCTs randomizing patients with atrial fibrillation to oral anticoagulants or either

placebo or antiplatelets.

Participants: 7933 adults with non-valvular atrial fibrillation.

Exposure: Predicted anticoagulant absolute risk reduction (ARR) by guideline-endorsed model

(CHA_2DS_2-VASc) vs. a Competing Risk Model that uses the same inputs as CHA_2DS_2-VASc but

accounts for the competing risk of death and allows for non-linear growth in benefit over time.

Main outcome measures: Ischemic stroke or systemic embolism

Results: 7933 participants had a median life expectancy of 8 years (IQR 6, 12), determined by

comorbidity-adjusted life tables. 43% were randomized to oral anticoagulation (median age 73

years, 36% women). The guideline-endorsed CHA_2DS_2-VASc model estimated a larger ARR

than the Competing Risk Model (median ARR at 3 years, 6.9% vs. 5.2%). ARR differences

varied by life expectancies: for those with life expectancies in the highest decile, 3-year ARR

difference (CHA_2DS_2-VASc model – Competing Risk Model 3-year risk) was -1.2% (42%

relative underestimation); for those with life expectancies in the lowest decile, 3-year ARR

difference was 5.9% (91% relative overestimation).

Conclusion and Relevance: Anticoagulants are exceptionally effective at reduced stroke risk.

However, anticoagulant benefits were misestimated with CHA_2DS_2-VASc, which does not

account for the competing risk of death nor decelerating treatment benefit over time.

Overestimation was most pronounced in patients with the lowest life expectancy and when

benefit was estimated over a multi-year horizon.

INTRODUCTION

Anticoagulants are the mainstay of preventative therapy for millions of older adults with atrial fibrillation. While anticoagulants reduce the risk of ischemic stroke and systemic embolism, they also increase the risk of bleeding. To help patients and clinicians weigh the risks and benefits of treatment, clinical guidelines and decision support tools endorse using the CHA_2DS_2-VASc score to estimate a patient's annual risk of ischemic stroke or systemic embolism without treatment.[1–5] The ACC/AHA/HRS consensus guidelines recommend that this baseline risk be used to estimate a patient's expected absolute risk reduction by applying the relative risk reduction from a meta-analysis of randomized trials.[1,6] Guidelines recommend anticoagulant therapy when the absolute risk reduction exceeds a threshold. The premise is that treatment benefits outweigh risks when an individual's estimated event risk exceeds this threshold.

While transparent, this approach makes two assumptions that can affect the accuracy of expected benefit. First, this approach does not account for the competing risk of death. A competing risk is an alternative outcome that occurs before, and necessarily precludes, the event of interest (e.g., cancer death before stroke from atrial fibrillation), thus limiting the absolute benefit achievable by anticoagulant treatment.[7–11] Competing risks are germane given the high all-cause mortality rate following a new diagnosis of atrial fibrillation—multiple studies estimate 20-25% mortality in the first year.[12–14] Second, this approach assumes that the therapeutic benefit continues to increase at a constant rate over time—that is, the risk of stroke over two years is twice the one-year risk and thus the absolute risk reduction over two years is twice the one-year absolute risk reduction. Both issues are readily addressed by estimating benefit using a competing risk model; however, it is unknown if doing so will materially affect absolute risk reduction estimates attributable to anticoagulants.

We used patient-level data from 12 randomized trials of anticoagulants for atrial fibrillation to determine if a competing risk model affects the measurement of absolute stroke

risk reduction. First, we compared the guideline-endorsed approach to measuring absolute risk

reduction (i.e., CHA_2DS_2-VASc score) to a competing risk model (i.e., Fine-Gray model[15]).

Second, we determined if differences in expected stroke risk reduction between the guideline-

endorse CHA_2DS_2-VASc approach and a competing risk model varied by life expectancy.

METHODS

Study design and participants

We used patient-level data from the Atrial Fibrillation Investigators (AFI) database which

contains patient-level data from 12 published clinical trials where patients were randomized to

full-dose oral anticoagulant (OAC), antiplatelets, or placebo. Trials include Atrial Fibrillation,

Aspirin, and Anticoagulation Study 1 (AFASAK-1),[16] AFASAK-2,[17] Boston Area Anticoagulation

Trial for Atrial Fibrillation (BAATAF),[18] Birmingham Atrial Fibrillation Treatment of the Aged

Study (BAFTA),[19] Canadian Atrial Fibrillation Anticoagulation (CAFA),[20] European Atrial

Fibrillation Trial (EAFT),[21] Primary Prevention of Arterial Thromboembolism in Atrial Fibrillation

(PAATAF),[22] National Study for Prevention of Embolism in Atrial Fibrillation (NASPEAF),[23] the

Stroke Prevention in Atrial Fibrillation 1 (SPAF-1),[24] SPAF-2,[25] SPAF-3,[26] and Stroke Prevention

in Non-rheumatic Atrial Fibrillation (SPINAF).[27] We did not include patients with mitral stenosis

and patients in SPAF-1, EAFT, PATAF, and SPAF-3 who were deemed ineligible to receive

anticoagulants (trial details in **Appendix 1** and **Appendix 2**).

Participant characteristics

Research coordinators and physicians collected patient characteristics before therapy

initiation. While specific features varied from study to study, common elements included a

history of stroke or transient ischemic attack, hypertension or systolic blood pressure ≥160

mmHg or use of antihypertensives, diabetes, angina, myocardial infarction, peripheral vascular

disease, smoking, and congestive heart failure, and body mass index. History of myocardial

infarction was not collected in NASPEAF and peripheral vascular disease was not collected in

AFASAK1, BAATAF, or BAFTA. Because history of myocardial infarction and peripheral

vascular disease were missing for all participants in specific trials, we assumed they were

missing at random and imputed them in 20 datasets using chained equations.[28] We excluded

<1% of participants who were missing data otherwise collected in a given trial (**Appendix 3**).

Treatment exposure

We examined all patients based on their treatment allocation (i.e., intention to treat).

Because studies have shown that antiplatelet and low-dose warfarin are ineffective

thromboprophylaxis in AF,[6] we categorized all trial participants as being randomized to full-dose

anticoagulants or control. Patients randomized to placebo, antiplatelets, low-dose warfarin, or

low-dose warfarin with aspirin were considered controls. AFASAK2, PAATAF, and SPAF3 used

low-dose warfarin and reported a mean international normalized ratio (INR) of < 1.5 supporting

their categorization as a control. While NASPEAF also had a low-dose anticoagulant arm, the

mean INR was 2.0 which is considered therapeutic[1]; therefore, we excluded participants

randomized to the NASPEAF low-dose anticoagulant arm.

Outcome ascertainment

The primary outcome was ischemic stroke or systemic embolism. We detail outcome

definitions by trial in **Appendix 4**. In general, trials defined ischemic stroke as a focal

neurological deficit lasting >24 hours. All trials except AFASAK-1 required a CT or MRI showing

the absence of blood. Systemic embolism was collected as an outcome in all but SPINAF and,

by and large, defined as an embolism to internal organs or limbs and required evidence via

angiography, surgery, or autopsy (**Appendix 4**). Patients were evaluated at 3- to 6-month

intervals or when a clinical outcome event was suspected. Except in AFASAK-1, a central

committee, blinded to intervention allocation, adjudicated all clinical events.

Life expectancy

We estimated the life expectancy of each participant at the time of trial enrollment using

the life table method.[29] We started with gender- and enrollment year-specific life tables from the

U.S. Centers for Disease Control and Prevention.[30] These tables, generated from population

data, predict annual mortality rates stratified by age, sex, and year. The life table method uses

annual mortality rates to calculate life expectancy. We used the life table method to estimate

each participant's life expectancy by adjusting the annual mortality rate for the additional

mortality risk associated with their comorbidities at the time of trial enrollment (**Appendix 5**).

Analysis

Our first analytic goal was to determine if using a competing risk framework generates

estimates of stroke risk reduction different from those of the guideline-endorsed CHA_2DS_2-VASc

model. To accomplish this and speak directly to guideline-recommended practice, we estimated

absolute risk reduction using the CHA_2DS_2-VASc score as the ACC/AHA/HRS guidelines

recommend.[1,2] Specifically, we assigned each patient an off-treatment risk of ischemic stroke or

systemic embolism corresponding to their CHA_2DS_2-VASc score. Rates come from the 2012

study by Friberg et al., which used the Swedish Atrial Fibrillation cohort to validate off-treatment

thromboembolic rates corresponding to each CHA_2DS_2-VASc score.[31] These rates are used in

patient-facing decision tools, online calculators, and decision analytic models.[5,32,33] To calculate

the absolute risk reduction, we multiplied the off-treatment stroke rate by 0.64, the guideline-

cited efficacy of anticoagulants.[1,6] Using this procedure for each patient, we estimated the

annual absolute risk reduction; this precise method is endorsed by the ACC/AHA/HRS Atrial

Fibrillation management guidelines to estimate benefit.[1] Because patients and physicians prefer

to make anticoagulant decisions using a 1-to-5-year time horizon,[5] we extrapolated this annual

reduction over five years, accounting for the declining at-risk population (**Appendix 6**).[34,35] The

same approach is also used in decision aids.[5]

Next, we estimated the absolute risk reduction using the Fine-Gray extension of the Cox

proportional hazards model, treating death unrelated to ischemic stroke or systemic embolism

as a competing event.[11] We fit a Fine-Gray model where time to ischemic stroke or systemic

embolism is a function of age (<65 years, 65-74 years, >75years), gender, congestive heart

failure, diabetes, hypertension, prior stroke or transient ischemic attack, and vascular disease

stratified by randomization to oral anticoagulants. These the same predictors used in the

CHA_2DS_2-VASc score. Then, we used the resulting treatment-stratified models to estimate the

cumulative incidence of ischemic stroke or systemic embolism for each participant given their

covariates at each study time point, assuming first they had been randomized to oral

anticoagulants and then assuming they had been randomized to control (i.e., predicted

values).[36,37] The difference between the two estimates represented the ARR for a given patient

at a given time point. We determined the misestimation of the CHA_2DS_2-VASc method as the

difference between the ARR estimated by CHA_2DS_2-VASc and the ARR estimated by the

Competing Risk Model. We used the paired t-test to determine if the two methods produced

statistically different estimates of benefit at each year after randomization.

Our second analytic goal was to determine if life expectancy predicted magnitude in the

CHA_2DS_2-VASc model misestimation. To achieve this, we determined the association between

life expectancy and misestimation of the CHA_2DS_2-VASc method over a 3-year horizon. We

chose 3 years since it is the midpoint between the 1-to-5 year horizon preferred by patients and

physicians and has been used in prior anticoagulation decision analyses.[5,38] We examined

misestimation of the CHA_2DS_2-VASc method by decile of life expectancy at trial enrollment,

hypothesizing that the misestimation would be greater at lower life expectancies.

We performed all statistical analyses using SAS 9.4 (Cary, NC). The study protocol was

approved by Institutional Review Boards at UCSF (21-34930) and MGH (2022P001783).

RESULTS

Patient characteristics and overall event rates

This study included 7933 patients from 12 randomized trials where 3407 (43%) were

randomized to oral anticoagulation (**Table 1**). The median age was 73 years at enrollment, 36%

were women, and the median CHA_2DS_2-VASc score was 3 [IQR 2, 4]. At enrollment, the

median life expectancy was 8 years [IQR 6, 12] (**Appendix 7**). Most patients (83%) ended the

follow-up period without a clinical event (median 731 days; IQR 415, 1025). (**Table 2**). In these

trials, 530 (7%) patients' first clinical event was an ischemic stroke or systemic embolism

(median 334 days; IQR 120, 580). Additionally, 630 (8%) patients died before a stroke or

systemic embolism (median 457 days; IQR 216, 772).

Comparison of absolute risk reduction estimates

Relative to the Competing Risk Model, the CHA_2DS_2-VASc model overestimated the

absolute risk reduction (ARR) of anticoagulants (**Figure 1**). As the time horizon increased, the

CHA_2DS_2-VASc estimate of median benefit increased linearly. In contrast, the Competing Risk

Model estimated a non-linear absolute risk reduction over time—while benefit increased over

time, it decelerated, i.e., absolute risk reduction grew by less each year. As a result, the

CHA$_2$DS$_2$-VASc model overestimated anticoagulation benefit as the time-horizon increased.

After 1 year, the CHA$_2$DS$_2$-VASc model and the Competing Risk Model produced clinically

similar estimates of absolute risk reduction (median ARR 2.3% by CHA$_2$DS$_2$-VASc estimate vs.

2.4% by Competing Risk Model, p<0.001). After 3 years, the CHA$_2$DS$_2$-VASc-based ARR was

clinically and statistically larger than the ARR from the Competing Risk Model (median ARR

6.9% vs. 5.2%, p<0.001). This difference increased when absolute risk reduction was estimated

over a 5-year horizon (median ARR 11.2% vs. 6.3%, p<0.001).

We assess whether the observed discrepancy in ARR could be because the guidelines

estimate of off-treatment stroke risk were produced in an external cohort and therefore were

miscalibrated (**Appendix 9**). The sensitivity showed that recalibration to the AFI database did

not meaningfully change the results presented in **Figure 1**.

Life expectancy and misestimation of benefit

As life expectancy decreased, the CHA$_2$DS$_2$-VASc model increasingly overestimated the

stroke and systemic embolism risk reduction attributable to anticoagulants in absolute and

relative terms (**Figure 2**). The figure plots the absolute and relative difference between the 3-

year ARR estimated by the CHA$_2$DS$_2$-VASc model and the Competing Risk Model by life

expectancy decile at trial enrollment. In the decile with the highest life expectancy (16 to 47

years), on average, over 3 years, the CHA$_2$DS$_2$-VASc model underestimated benefit by 1.2%

(95% CI 1.1% to 1.3%) in absolute terms and 42% (95% CI 40% to 45%) in relative terms. By

comparison, in the decile with the lowest life expectancy (1 to 4 years), on average over 3

years, the CHA$_2$DS$_2$-VASc model overestimated benefit by 5.9% (95% CI 5.6% to 6.1%) in

absolute terms and 91% (95% CI 87% to 95%) in relative terms.

DISCUSSION

Using patient-level data from 12 randomized trials, we demonstrated that while anticoagulants effectively reduce ischemic stroke and systemic embolism risk, failing to use a competing risks framework resulted in a meaningful overestimation of treatment benefit. This finding was most pronounced when risk reduction was estimated over a multi-year horizon. Further, we showed that as life expectancy decreased, treatment benefit was increasingly overestimated. While those with the highest life expectancy may benefit more than guideline estimates would suggest, benefit for those with the lowest life expectancy was strikingly overestimated.

The study results directly apply to the AHA/ACC/HRS[1,2] and European Society of Cardiology (ESC)[3] atrial fibrillation guidelines in which the cornerstone of anticoagulant decision-making is estimating the absolute risk reduction. Guidelines ask clinicians to estimate the off-treatment stroke risk using the CHA_2DS_2-VASc score and to use that baseline risk to infer the probable absolute risk reduction. Anticoagulants are recommended above a CHA_2DS_2-VASc score threshold—i.e., when the absolute risk reduction exceeds a threshold. Thus, if clinical guidelines continue to recommend treatment using an absolute risk reduction threshold, these results suggest guidelines should re-estimate benefit using a competing risk framework. At the very least, guidelines should acknowledge that current methods overestimate benefits for those with limited life expectancy and when estimating benefits over a multi-year horizon.

The current study's findings should influence anticoagulant decision aids for patients with atrial fibrillation. To advance anticoagulant shared decision-making, investigators and professional societies have developed conversation aids that display a patient's risk of stroke with and without anticoagulants. For example, the American College of Cardiology's CardioSmart tool and the Mayo Clinic Anticoagulation Choice Decision Aid both display a pictogram of absolute risk with and without treatment to communicate treatment effects.[4,5]

These implementation tools are built to reflect clinical guidelines and do so faithfully. However,

both should note that benefit estimates are overstated for those with limited life expectancy and

when benefit is estimated over a multi-year horizon.

These results also lend credence to physicians for whom advanced age, frailty, and

function—all significant determinants of life expectancy—factor in their anticoagulant decision-

making.[39,40] Adults aged 65 years and older constitute 80% of all American adults with atrial

fibrillation.[41] Further, prior work indicates that many older adults with atrial fibrillation have

geriatric syndromes (e.g., dependency in activities of daily living) known to be associated with a

reduced life expectancy.[42,43] In this study, we estimated life expectancy using basic medical

comorbidity data available in the trial database. Modern, more accurate tools go beyond

comorbidities using physical function, cognition, and self-reported health to estimate life

expectancy.[44,45] Life expectancy estimates from such tools are routinely used to inform the risk

and benefits of interventions in older adults (e.g., cancer screening). Until guidelines formally

account for it, clinicians may consider using life expectancy to guide the discussion about the

benefit of anticoagulants when treating older adults. This may be particularly relevant when

treating patients with both a limited life expectancy and borderline CHA_2DS_2-VASc scores.

Finally, these findings should inform the methods used to develop and validate future

stroke risk models. While the CHA_2DS_2-VASc score continues to be endorsed by U.S. and

European guidelines, investigators are actively developing a new generation of stroke risk

prediction models. Contemporary models like the ABC stroke risk score, CARS, and the ATRIA

stroke model all outperform the CHA_2DS_2-VASc score.[46–48] However, none used an analysis

framework that both accounts for the competing risk of death and changing risk over a multi-

year horizon. The ABC model establishes a non-linear stroke risk by showing 3-year risk is not

simply three times the 1-year risk, findings that were redemonstrated in this paper. When

developing the ABC model, Hijazi et al. also conducted a sensitivity analysis comparing their

model to a competing risk model.[46] They found a tight correlation when risk was estimated over

a 1-year horizon, results mirrored in this study. We expanded on their work by showing that this

correlation was weaker when using a longer time horizon (e.g., 3 years). More importantly, we

identified substantial heterogeneity—as life expectancy decreased, overestimation increased.

There are limitations to this study inherent to the data available and the study design.

First, this study relied on data from RCTs conducted between 1989 and 2007 and thus may be

only partially representative of contemporary patients with atrial fibrillation. Specific differences

include the risk of stroke and death from non-atrial fibrillation causes and the added safety of

direct-acting anticoagulants.[49] This limitation is balanced by the fact that the AFI cohort is one of

the largest patient-level atrial fibrillation cohorts where anticoagulant treatment was randomized

against placebo and antiplatelets. The results were unaffected by selection bias that hampers

contemporary risk models developed in observational cohorts. More importantly, while dated,

these trials are the foundation upon which current guidelines recommend anticoagulants.

Second, this study could not address the relationship between life expectancy and the potential

misestimation of anticoagulant harm. Specifically, the AF Investigators database does not

include inputs used in contemporary hemorrhage prediction tools (e.g., ATRIA bleed, HAS-

BLED). While it is important to consider the effect a competing risk framework may have on

estimating the risk of bleeding, current guidelines do not incorporate bleeding risk into treatment

recommendations. For example, for patients with scores above the CHA_2DS_2-VASc treatment

threshold, guideline recommendations do not change whether the bleeding risk is high or low.

Finally, because nationality was unavailable for study participants, we relied on U.S. life tables

to calculate life expectancy.

In summary, we showed that while oral anticoagulants were clearly effective, treatment

benefit was overstated when using the guideline-endorsed approach because guidelines do not

account for the competing risk of death and assume a constant growth in treatment benefit over

time. Overestimation was most pronounced in patients with the lowest life expectancy and when

benefit was estimated over a multi-year horizon. These findings should inform guidelines and

decision aids, clinicians treating patients with limited life expectancy, and investigators

developing stroke risk prediction models.

ACKNOWLEDGMENTS

We thank Dr. Sei Lee, Professor of Medicine at UCSF, for his valuable methodological feedback. Dr. Shah had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Author contributions: Dr. Shah had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors listed have contributed sufficiently to the project to be included as authors, and all those who are qualified to be authors are listed in the author byline.

Conflict of Interest Disclosure: Dr. Shah, Dr. Jeon, Dr. Boscardin, and Dr. Covinsky reported funding from the National Institute on Aging/National Institutes of Health related to the conduct of this study (noted below). Dr. Fang reported grants from the National Heart, Lung, and Blood Institute/National Institutes of Health during the conduct of the study (K24HL141354) and grants from Patient-Centered Outcomes Research Institute outside the submitted work. Dr. Singer was supported, in part, by the Eliot B. and Edith C. Shoolman Fund of Massachusetts General Hospital. He has received research support from Bristol Myers Squibb and consultancy fees from Bristol-Myers Squibb, Fitbit, Medtronic, and Pfizer. Professor Hobbs is, in part, supported by the NIHR (ARC OTV and MIC) and has received occasional consultancy fees from Bayer, BMS Pfizer, Novartis, and AZ unconnected to this study.

Funding: This study was funded by the NIA (K76AG074919, P30AG044281).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data sharing: Researchers can apply to the AF Investigators for data access.

REFERENCES

1.   January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline
for the Management of Patients With Atrial Fibrillation: A Report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart
Rhythm Society. *J Am Coll Cardiol.* 2014;64(21):e1-e76. doi:10.1016/j.jacc.2014.03.022

2.   January C, Wann L. Samuel, Calkins Hugh, et al. 2019 AHA/ACC/HRS Focused Update of
the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation:
A Report of the American College of Cardiology/American Heart Association Task Force
on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the
Society of Thoracic Surgeons. *Circulation.* 2019;140(2):e125-e151.
doi:10.1161/CIR.0000000000000665

3.   Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and
management of atrial fibrillation developed in collaboration with the European Association
for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* 2021;42(5):373-498.
doi:10.1093/eurheartj/ehaa612

4.   Atrial Fibrillation | CardioSmart – American College of Cardiology. CardioSmart. Accessed
December 23, 2020. http://www.cardiosmart.org/topics/atrial-fibrillation

5.   Zeballos-Palacios CL, Hargraves IG, Noseworthy PA, et al. Developing a Conversation Aid
to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice.
Mayo Clin Proc. 2019;94(4):686-696. doi:10.1016/j.mayocp.2018.08.030

6.   Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic Therapy to Prevent Stroke
in Patients Who Have Nonvalvular Atrial Fibrillation. *Ann Intern Med.* 2007;146(12):857-
867. doi:10.7326/0003-4819-146-12-200706190-00007

7.   Austin PC, Fine JP. Accounting for competing risks in randomized controlled trials: a
review and recommendations for improvement. *Stat Med.* 2017;36(8):1203-1209.
doi:10.1002/sim.7215

8.   Koller MT, Raatz H, Steyerberg EW, Wolbers M. Competing risks and the clinical
community: irrelevance or ignorance? *Stat Med.* 2012;31(11-12):1089-1097.
doi:10.1002/sim.4384

9.   Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on
competing risks in survival data analysis. *Br J Cancer.* 2004;91(7):1229-1235.
doi:10.1038/sj.bjc.6602102

10. Berry SD, Ngo L, Samelson EJ, Kiel DP. Competing Risk of Death: An Important
Consideration in Studies of Older Adults. *J Am Geriatr Soc.* 2010;58(4):783-787.
doi:10.1111/j.1532-5415.2010.02767.x

11. Austin Peter C., Lee Douglas S., Fine Jason P. Introduction to the Analysis of Survival
Data in the Presence of Competing Risks. *Circulation.* 2016;133(6):601-609.
doi:10.1161/CIRCULATIONAHA.115.017719

12. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of Atrial
Fibrillation on the Risk of Death: The Framingham Heart Study. *Circulation*.
1998;98(10):946-952. doi:10.1161/01.CIR.98.10.946

13. Piccini Jonathan P., Hammill Bradley G., Sinner Moritz F., et al. Incidence and Prevalence
of Atrial Fibrillation and Associated Mortality Among Medicare Beneficiaries: 1993–2007.
Circ Cardiovasc Qual Outcomes. 2012;5(1):85-93.
doi:10.1161/CIRCOUTCOMES.111.962688

14. Siontis KC, Gersh BJ, Weston SA, et al. Associations of Atrial Fibrillation After Noncardiac
Surgery With Stroke, Subsequent Arrhythmia, and Death: A Cohort Study. *Ann Intern Med*.
Published online July 26, 2022:M22-0434. doi:10.7326/M22-0434

15. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing
Risk. *J Am Stat Assoc*. 1999;94(446):496-509. doi:10.2307/2670170

16. Petersen P, Godtfredsen J, Boysen G, Andersen E, Andersen B. PLACEBO-
CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR
PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL
FIBRILLATION: The Copenhagen AFASAK Study. *The Lancet*. 1989;333(8631):175-179.
doi:10.1016/S0140-6736(89)91200-2

17. Gulløv AL, Koefoed BG, Petersen P, et al. Fixed Minidose Warfarin and Aspirin Alone and
in Combination vs Adjusted-Dose Warfarin for Stroke Prevention in Atrial Fibrillation:
Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. *Arch Intern
Med*. 1998;158(14):1513-1521. doi:10.1001/archinte.158.14.1513

18. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, Singer DE, Hughes
RA, et al. The effect of low-dose warfarin on the risk of stroke in patients with
nonrheumatic atrial fibrillation. *N Engl J Med*. 1990;323(22):1505-1511.
doi:10.1056/NEJM199011293232201

19. Mant J, Hobbs FR, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an
elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation
Treatment of the Aged Study, BAFTA): a randomised controlled trial. *The Lancet*.
2007;370(9586):493-503. doi:10.1016/S0140-6736(07)61233-1

20. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian atrial
fibrillation anticoaguiation (CAFA) study. *J Am Coll Cardiol*. 1991;18(2):349-355.
doi:10.1016/0735-1097(91)90585-W

21. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-
rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. *The Lancet*.
1993;342(8882):1255-1262. doi:10.1016/0140-6736(93)92358-Z

22. Hellemons BSP, Langenberg M, Lodder J, et al. Primary prevention of arterial
thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled
trial comparing two intensities of coumarin with aspirin. *BMJ*. 1999;319(7215):958-964.
doi:10.1136/bmj.319.7215.958

23.   Pérez-Gómez F, Alegría E, Berjón J, et al. Comparative effects of antiplatelet,
355   anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial
356   fibrillation: A randomized multicenter study. *J Am Coll Cardiol*. 2004;44(8):1557-1566.
357   doi:10.1016/j.jacc.2004.05.084

358   24.   Preliminary Report of the Stroke Prevention in Atrial Fibrillation Study. *N Engl J Med*.
359   1990;322(12):863-868. doi:10.1056/NEJM199003223221232

360   25.   Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention
361   of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. *The
362   Lancet*. 1994;343(8899):687-691. doi:10.1016/S0140-6736(94)91577-6

363   26.   Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-
364   intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke
365   Prevention in Atrial Fibrillation III randomised clinical trial. *The Lancet*.
366   1996;348(9028):633-638. doi:10.1016/S0140-6736(96)03487-3

367   27.   Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke
368   associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in
369   Nonrheumatic Atrial Fibrillation Investigators. *N Engl J Med*. 1992;327(20):1406-1412.
370   doi:10.1056/NEJM199211123272002

371   28.   White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and
372   guidance for practice. *Stat Med*. 2011;30(4):377-399. doi:https://doi.org/10.1002/sim.4067

373   29.   *Method for Constructing Complete Annual U.S. Life Tables*. National Center for Health
374   Statistics; 1999:36.

375   30.   The Berkeley Mortality Database. Accessed November 3, 2021. http://bmd.mortality.org/

376   31.   Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic
377   stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation
378   cohort study. *Eur Heart J*. 2012;33(12):1500-1510. doi:10.1093/eurheartj/ehr488

379   32. CHA_2DS_2-VASc Score for Atrial Fibrillation Stroke Risk - MDCalc. Accessed October 11,
380   2022. https://www.mdcalc.com/calc/801/cha2ds2-vasc-score-atrial-fibrillation-stroke-risk

381   33.   Eckman MH, Wise RE, Naylor K, et al. Developing an Atrial Fibrillation Guideline Support
382   Tool (AFGuST) for shared decision making. *Curr Med Res Opin*. 2015;31(4):603-614.
383   doi:10.1185/03007995.2015.1019608

384   34.   Miller DK, Homan SM. Determining Transition Probabilities: Confusion and Suggestions.
385   *Med Decis Making*. 1994;14(1):52-58. doi:10.1177/0272989X9401400107

386   35.   Rothman KJ. *Epidemiology: An Introduction*. Oxford University Press; 2002.
387   https://books.google.com/books?id=f3gItAEACAAJ

388   36.   Bieler GS, Brown GG, Williams RL, Brogan DJ. Estimating Model-Adjusted Risks, Risk
389   Differences, and Risk Ratios From Complex Survey Data. *Am J Epidemiol*.
390   2010;171(5):618-623. doi:10.1093/aje/kwp440

391   37.   Graubard BI, Korn EL. Predictive Margins with Survey Data. *Biometrics*. 1999;55(2):652-
392   659. doi:10.1111/j.0006-341X.1999.00652.x

393   38.   Shah Sachin J., Singer Daniel E., Fang Margaret C., Reynolds Kristi, Go Alan S., Eckman
394   Mark H. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial
395   Fibrillation. *Circ Cardiovasc Qual Outcomes*. 2019;12(11):e006212.
396   doi:10.1161/CIRCOUTCOMES.119.006212

397   39.   Ashburner JM, Atlas SJ, Khurshid S, et al. Electronic physician notifications to improve
398   guideline-based anticoagulation in atrial fibrillation: a randomized controlled trial. *J Gen
399   Intern Med*. Published online August 3, 2018. doi:10.1007/s11606-018-4612-6

400   40.   McGrath ER, Go AS, Chang Y, et al. Use of Oral Anticoagulant Therapy in Older Adults
401   with Atrial Fibrillation After Acute Ischemic Stroke. *J Am Geriatr Soc*. 2017;65(2):241-248.
402   doi:10.1111/jgs.14688

403   41.   Go AS, Hylek EM, Phillips KA, et al. Prevalence of Diagnosed Atrial Fibrillation in Adults:
404   National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation
405   and Risk Factors In Atrial Fibrillation (ATRIA) Study. *JAMA*. 2001;285(18):2370-2375.
406   doi:10.1001/jama.285.18.2370

407   42.   Shah SJ, Fang MC, Jeon SY, Gregorich SE, Covinsky KE. Geriatric Syndromes and Atrial
408   Fibrillation: Prevalence and Association with Anticoagulant Use in a National Cohort of
409   Older Americans. *J Am Geriatr Soc*. 2021;69(2):349-356. doi:10.1111/jgs.16822

410   43.   Kane RL, Shamliyan T, Talley K, Pacala J. The Association Between Geriatric Syndromes
411   and Survival. *J Am Geriatr Soc*. 2012;60(5):896-904. doi:10.1111/j.1532-
412   5415.2012.03942.x

413   44.   Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and Validation of a Prognostic
414   Index for 4-Year Mortality in Older Adults. *JAMA*. 2006;295(7):801-808.
415   doi:10.1001/jama.295.7.801

416   45.   Schonberg MA, Davis RB, McCarthy EP, Marcantonio ER. Index to Predict 5-Year
417   Mortality of Community-Dwelling Adults Aged 65 and Older Using Data from the National
418   Health Interview Survey. *J Gen Intern Med*. 2009;24(10):1115-1122. doi:10.1007/s11606-
419   009-1073-y

420   46.   Hijazi Z, Lindbäck J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke
421   risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. *Eur Heart
422   J*. 2016;37(20):1582-1590. doi:10.1093/eurheartj/ehw054

423   47.   Lee CJY, Toft-Petersen AP, Ozenne B, et al. Assessing absolute stroke risk in patients
424   with atrial fibrillation using a risk factor-based approach. *Eur Heart J - Cardiovasc
425   Pharmacother*. 2021;7(FI1):f3-f10. doi:10.1093/ehjcvp/pvaa063

426   48.   Singer DE, Chang Y, Borowsky LH, et al. A New Risk Scheme to Predict Ischemic Stroke
427   and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score. *J
428   Am Heart Assoc*. 2013;2(3):e000250. doi:10.1161/JAHA.113.000250

429   49.   Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new
430   oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of
431   randomised trials. *The Lancet*. 2014;383(9921):955-962.

Table 1: Characteristics of patients with atrial fibrillation in 12 randomized trials

Characteristic	n=7933
Age, years (median [IQR])	73 [67, 78]
Gender	
Male	5040 (64%)
Female	2893 (36%)
Diabetes	
No	6780 (85%)
Yes	1153 (15%)
Hypertension	
No	4049 (51%)
Yes	3884 (49%)
Congestive heart failure	
No	5533 (70%)
Yes	2400 (30%)
Prior stroke	
No	6413 (81%)
Yes	1520 (19%)
Angina	
No	6566 (83%)
Yes	1367 (17%)
Prior myocardial infarction	
No	6514 (82%)
Yes	876 (11%)
Missing*	543 (7%)
Peripheral vascular disease	
No	5109 (64%)
Yes	429 (5%)
Missing[†]	2395 (30%)
Body mass index kg/m^2 (median [IQR])	
BMI among those with data	26 [24, 29]
Missing[‡]	2070 (26%)
Smoking status	
Never smoker	2427 (31%)
Former smoker	1843 (23%)
Current smoker	790 (10%)
Missing[§]	2873 (36%)
CHA$_2$DS$_2$-VASc score	

Score (median [IQR])	3 [2, 4]
Missing⁻	2938 (37%)
Trial	
AFASAK1	1002 (13%)
AFASAK2	677 (9%)
BAATAF	420 (5%)
BAFTA	973 (12%)
CAFA	375 (5%)
EAFT	661 (8%)
NASPEAF	543 (7%)
PATAF	364 (5%)
SPAF1	208 (3%)
SPAF2	1098 (14%)
SPAF3	1044 (13%)
SPINAF	568 (7%)
Randomized study arm assignment	
Warfarin	3407 (43%)
Control¶	4526 (57%)

Legend

AFASAK - Atrial Fibrillation, Aspirin, and Anticoagulation Study; BAATAF - Boston Area Anticoagulation Trial for Atrial Fibrillation; BAFTA - Birmingham Atrial Fibrillation Treatment of the Aged Study; CAFA - Canadian Atrial Fibrillation Anticoagulation; EAFT - European Atrial Fibrillation Trial; PAATAF - Primary Prevention of Arterial Thromboembolism in Atrial Fibrillation; NASPEAF - National Study for Prevention of Embolism in Atrial Fibrillation; SPAF - Stroke Prevention in Atrial Fibrillation; SPINAF - Stroke Prevention in Non-rheumatic Atrial Fibrillation

* History of myocardial infarction was not available for NSPEAF trial participants

† History of peripheral vascular disease was not available for AFASAK1, BAATAF, or BAFTA trial participants

‡ Height and weight were not available for BAATAF or AFASAK2 trial participants

§ Smoking status was not available for AFASAK1, CAFA, or BAFTA participants. In EAFT, data collection did not distinguish between former and never smokers

⧠ CHA_2DS_2-VASc scores are for those with complete cases. It excludes 2395 participants enrolled in trials where peripheral vascular disease data are not available, and 543 participants enrolled in trials where history of myocardial infarction was not available.

¶ Control includes those assigned placebo, aspirin, low-dose warfarin, or low-dose warfarin an aspirin. Patients enrolled in SPAF3 and AFASAK2 and assigned to low-dose warfarin had a mean internal normalized ratio (INR) of < 1.5 supporting their categorization as a control. Patients enrolled in NASPEAF and randomized to low-dose anticoagulant had a mean INR of 2.0 and were therefore not included as a control.

Since missing data were missing for entire trials, they were assumed to be missing completely at random.

Table 2: Trial outcomes, rates and follow-up time

First clinical outcome	Events (%)	Days from randomization, median (IQR)
Ischemic stroke or systemic embolism	530 (7%)	334 (120, 580)
Systemic bleed	175 (2%)	413 (163, 731)
Intracranial hemorrhage	29 (0%)	300 (201, 620)
Death, all-cause	630 (8%)	457 (216, 772)
Study end without a clinical event	6569 (83%)	731 (415, 1025)

Figure 1: Estimated median absolute risk reduction by CHA$_2$DS$_2$-VASc model compared with Competing Risk Model

<u>Legend</u>

For each patient in the cohort, we estimate the absolute risk reduction attributable to oral anticoagulation annually for 5 years using the CHA$_2$DS$_2$-VASc model and again using a Fine-Gray model, a survival model that accounts for the competing risk of death. We plot the median benefit at each time point. We graphed the median ARR because the CHA$_2$DS$_2$-VASc model produces discrete estimates of benefit (i.e., not normally distributed). Data are presented as a table in **Appendix 10**. Component on- and off-treatment cumulative incidence rates also displayed in **Appendix 10.**

Figure 2: Misestimation of Stroke Risk Reduction by CHA$_2$DS$_2$-VASc score at 3 years,

(A) Absolute misestimation

(B) Relative misestimation

Legend

Absolute misestimation is defined as: $ARR_{CHA2DS2-VASc} - ARR_{Competing\ Risk\ Model}$.

Relative misestimation is defined as: $ARR_{CHA2DS2-VASc} / ARR_{Competing\ Risk\ Model} - 1$.

The dot represents the mean overestimation, and the error bars represent the 95% confidence interval of the mean. The misestimation of absolute risk reduction (ARR) is calculated for each patient as the difference between the ARR computed by the CHA_2DS_2-VASc score and the ARR computed by the Fine-Gray model, a survival model that accounts for the competing risk of death. Positive numbers represent the overestimation of the CHA_2DS_2-VASc model. Tabular results can be found in **Appendix 11.**